Malaria research and its influence on anti-malarial drug policy in Malawi: a case study

Home
→
HSRC Research Outputs
→
Public
→
View Item

dc.date.accessioned	2022-08-17T15:46:52Z
dc.date.available	2022-08-17T15:46:52Z
dc.date.issued	2016-06-14	en
dc.identifier.uri	http://hdl.handle.net/20.500.11910/10288
dc.description.abstract	In 1993, Malawi changed its first-line anti-malarial treatment for uncomplicated malaria from chloroquine to sulfadoxine-pyrimethamine (SP), and in 2007, it changed from SP to lumefantrine-artemether. The change in 1993 raised concerns about whether it had occurred timely and whether it had potentially led to early development of Plasmodium falciparum resistance to SP. This case study examined evidence from Malawi in order to assess if the policy changes were justifiable and supported by evidence.	en
dc.format.medium	Print	en
dc.subject	MALARIA	en
dc.subject	MALAWI	en
dc.subject	DRUG USE	en
dc.subject	POLICY IMPLEMENTATION	en
dc.title	Malaria research and its influence on anti-malarial drug policy in Malawi: a case study	en
dc.type	Journal Article	en
dc.description.version	Y	en
dc.ProjectNumber	N/A	en
dc.Volume	14(1)	en
dc.BudgetYear	2016/17	en
dc.ResearchGroup	Population Health, Health Systems and Innovation	en
dc.SourceTitle	Health Research Policy and Systems	en
dc.ArchiveNumber	9244	en
dc.URL	http://ktree.hsrc.ac.za/doc_read_all.php?docid=16531	en
dc.PageNumber	Online	en
dc.outputnumber	8051	en
dc.bibliographictitle	Mwendera, C., De Jager, C., Longwe, H., Phiri, K., Hongoro, C. & Mutero, C.M. (2016) Malaria research and its influence on anti-malarial drug policy in Malawi: a case study. Health Research Policy and Systems. 14(1):Online. http://hdl.handle.net/20.500.11910/10288	en
dc.publicationyear	2016	en
dc.contributor.author1	Mwendera, C.	en
dc.contributor.author2	De Jager, C.	en
dc.contributor.author3	Longwe, H.	en
dc.contributor.author4	Phiri, K.	en
dc.contributor.author5	Hongoro, C.	en
dc.contributor.author6	Mutero, C.M.	en